Drug intelligence / Profile preview

AI-1178

Development stage: Preclinical
Lead developer: Apeximmune Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AI-1178 is a monoclonal antibody drug candidate developed by Apeximmune Therapeutics. It functions as an inhibitor of signal-regulatory protein alpha (SIRPα), a cell surface protein involved in immune regulation. By blocking SIRPα, AI-1178 is designed to enhance the anti-tumor activity of immune cells, particularly macrophages, by disrupting the "don't eat me" signal that cancer cells use to evade immune destruction. The primary therapeutic area for AI-1178 is neoplasms (cancers). As of January 2025, its highest development status globally is preclinical[1][2].

Targets

SIRPA (Signal-regulatory protein alpha)

Beyond the preview

Go deeper on AI-1178.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AI-1178.

Explore the full profile